Welcome to our dedicated page for Azitra news (Ticker: AZTR), a resource for investors and traders seeking the latest updates and insights on Azitra stock.
Azitra, Inc. (NYSE American: AZTR) is a clinical stage biopharmaceutical company developing therapies for precision dermatology, and its news flow reflects the progress and challenges of an emerging biotechnology issuer. Company announcements frequently highlight updates on its lead program, ATR-12, which uses an engineered strain of Staphylococcus epidermidis to treat Netherton syndrome, a rare, chronic skin disease with no approved treatment options. News items also cover milestones for ATR-04, an engineered S. epidermidis program for EGFR inhibitor (EGFRi)–associated rash and skin toxicity, and ATR-01, a preclinical program designed to treat ichthyosis vulgaris through filaggrin secretion.
Investors following AZTR news can expect regular coverage of clinical trial milestones, such as initiation of Phase 1b and Phase 1/2 studies, first-patient-dosed events, and the presentation of preclinical and clinical data at scientific and investor conferences. The company’s releases describe participation in events like BIO-Europe, Biotech Showcase, and investment conferences, where management discusses safety data, pharmacology results, and development strategy for ATR-12, ATR-04, and ATR-01.
News about Azitra also includes regulatory and listing developments, including notices from NYSE American regarding compliance with continued listing standards and acceptance of the company’s plan to regain compliance by a specified deadline. Additional articles cover capital markets activity, such as private placements, equity line of credit transactions, and related registration statements and proxy proposals tied to share issuances and warrants.
By monitoring this AZTR news page, readers can track how Azitra advances its live biotherapeutic and engineered protein programs in dermatology, how it responds to stock exchange compliance requirements, and how it structures financings to support ongoing clinical and preclinical work.
Azitra (NYSE: AZTR) announced cancellation of its special meeting of stockholders that had been originally scheduled for February 6, 2026 and adjourned to March 6, 2026 due to a lack of quorum.
The company is a clinical‑stage biopharmaceutical developer of engineered S. epidermidis programs, including ATR-12 (Phase 1b for Netherton syndrome) and ATR-04 (FDA Fast Track for EGFRi associated rash; open IND). Azitra’s platform includes ~1,500 bacterial strains and AI/ML screening tools.
Azitra (NYSE American: AZTR) reported full-year 2025 results and clinical progress. Key clinical advances include dosing the first patient in the Phase 1/2 ATR-04 trial (EGFRi-associated rash), Fast Track designation for ATR-04, promising Phase 1b safety data for ATR-12 in Netherton syndrome, and positive preclinical ATR-01 data.
Financials: R&D $4.8M, G&A $6.2M, net loss $11.0M, and cash & equivalents $2.1M; completed $8.5M financing activity in 2025.
Azitra (NYSE:AZTR) added The University of Texas MD Anderson Cancer Center as a clinical site for its Phase 1/2 study of topical ATR-04 (ATR04-484) for EGFR inhibitor-associated skin rash.
The multicenter, randomized, double-blind study (NCT06830863) is enrolling Cohort 1 (anticipated eight patients). ATR-04 has FDA Fast Track designation and an open IND.
Azitra (NYSE American: AZTR) will present at the BIO Investment & Growth Summit in Miami Beach on March 2-3, 2026, with a formal presentation on March 2 at 2:15 PM ET.
Management will highlight pipeline updates for ATR-12 (Phase 1b), ATR-04 (Phase 1/2) and ATR-01 (IND-enabling), and hold one-on-one investor meetings.
Azitra (NYSE American: AZTR) adjourned its virtual Special Meeting held Feb 6, 2026, to March 6, 2026 at 11:00 a.m. ET because a quorum was not present. Proxies then represented approximately 13% of outstanding voting shares; a quorum requires 33 1/3%.
The Reconvened Special Meeting will consider two proposals: approval to issue more than 19.99% of outstanding common stock underlying warrants under a Nov 24, 2025 Purchase Agreement with Alumni Capital LP, and a potential adjournment to solicit additional proxies.
Azitra (NYSE American: AZTR) will present at Biotech Showcase in San Francisco on January 13, 2026 at 2:30 PM PT. Management will hold one-on-one meetings with registered investors and potential partners to review the company's clinical development strategy, recent corporate achievements, and anticipated milestones.
The presentation will be delivered by Travis Whitfill, Chief Operating Officer, at the Hilton San Francisco Union Square (Yosemite C, Ballroom Level). Registration is available through the event website for accredited attendees.
Azitra (NYSE: AZTR) received NYSE American staff approval of its listing standards compliance plan under Section 1003(a)(ii).
Azitra previously received a notice for not meeting the $4.0 million minimum stockholders' equity requirement after reporting losses in three of the last four fiscal years. The company must regain compliance by April 1, 2027 or face potential delisting. Azitra will remain listed during monitoring and is exploring multiple funding avenues to achieve compliance.
Azitra (NYSE American: AZTR) entered a private placement with a single institutional investor to sell 4,687,500 shares of common stock (or pre-funded warrants in-lieu) together with warrants to purchase up to 4,687,500 shares.
The combined effective offering price per share plus warrant is $0.32, producing estimated gross proceeds of approximately $1.5 million before placement agent fees and expenses. The warrants have an exercise price of $0.32, will be exercisable upon shareholder approval, and expire five years after that approval. The Offering is expected to close on or about November 25, 2025. Maxim Group is sole placement agent. The company has agreed to file a resale registration statement with the SEC.
Azitra (NYSE American: AZTR) reported Q3 2025 results and business updates on Nov 12, 2025. Key operational highlights: dosed first patient in the Phase 1/2 ATR-04 trial for EGFRi-associated rash (Aug 2025) and presented positive preclinical data for ATR-01 at BIO-Europe. The company raised $2.8M under an equity line with Alumni Capital LP. Financials: R&D expense was $1.2M (Q3 2025) vs $1.0M (Q3 2024); G&A was $1.6M vs $1.9M; net loss was $2.8M vs $1.0M; cash and cash equivalents were $1.4M as of Sept 30, 2025.
The company said it continues to advance ATR-12, ATR-04, and ATR-01 programs derived from its topical live biotherapeutic platform.
Azitra (NYSE American: AZTR) on Nov. 7, 2025 denied a circulated report that it had priced a $44 million registered direct offering. The company said the report is false and urged investors to rely only on information issued through its official channels. Azitra also said it is taking steps to identify the source of the false report.